

## Author index

### Volume 129 (1997)

Adams, M.R., R. McCredie, W. Jessup, J. Robinson, D. Sullivan, D.S. Celermajer, Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease **129**, 261

Arima, N., see Miyamoto, T. **129**, 207

Asayama, K., see Hayashibe, H. **129**, 53

Ashby, J.P., see Wenham, P.R. **129**, 185

Azakami, S., see Miyamoto, T. **129**, 207

Bagga, M., see Millican, S.A. **129**, 17

Barter, P., see Nestel, P. **129**, 231

Bauer, P., see Neunteufl, T. **129**, 111

Baum, K., see Kontush, A. **129**, 119

Beisiegel, U., see Kontush, A. **129**, 119

Bondjers, G., see Maxwell, S. **129**, 89

Brayne, C.E., see Galinsky, D. **129**, 177

Brunet, S., F. Guertin, L. Thibault, V. Gavino, E. Delvin, E. Levy, Iron-salicylate complex induces peroxidation, alters hepatic lipid profile and affects plasma lipoprotein composition **129**, 159

Candlish, J.K., N. Saha, J.W. Mak, Plasma lipids and apolipoproteins in a population of Orang Asli ('aborigines') from West Malaysia **129**, 49

Celermajer, D.S., see Adams, M.R. **129**, 261

Clifton, P., see Nestel, P. **129**, 231

Colquhoun, D., see Nestel, P. **129**, 231

Cremer, P., D. Nagel, H. Mann, B. Labrot, R. Müller-Berninger, H. Elster, D. Seidel, Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men **129**, 221

Delvin, E., see Brunet, S. **129**, 159

Demacker, P.N.M., see Mol, M.J.T.M. **129**, 169

Dening, T.R., see Galinsky, D. **129**, 177

de Rijke, Y.B., see Mol, M.J.T.M. **129**, 169

Dhall, D.P., see Shats, E.A. **129**, 9

Easton, D.F., see Galinsky, D. **129**, 177

Eddy, R., see Millican, S.A. **129**, 17

Edwards, R.J., see Powell, J.T. **129**, 41

Ehnholm, C., see Ylitalo, K. **129**, 271

Eliasson, B., N. Mero, M.-R. Taskinen, U. Smith, The insulin resistance syndrome and postprandial lipid intolerance in smokers **129**, 79

Elster, H., see Cremer, P. **129**, 221

Eto, M., see Saito, M. **129**, 73

Finckh, B., see Kontush, A. **129**, 119

Forster, B.A., P.D. Weinberg, Evans' blue dye abolishes endothelium-dependent relaxation of rabbit aortic rings **129**, 129

Franks, P.J., see Powell, J.T. **129**, 41

Fuse, T., see Igarashi, M. **129**, 27

Galinsky, D., C. Tysoe, C.E. Brayne, D.F. Easton, F.A. Huppert, T.R. Dening, E.S. Paykel, D.C. Rubinsztein, Analysis of the apo E/apo C-I, angiotensin converting enzyme and methylenetetrahydrofolate reductase genes as candidates affecting human longevity **129**, 177

Gavino, V., see Brunet, S. **129**, 159

Glogar, D., see Neunteufl, T. **129**, 111

Görög, P., Modified low density lipoprotein is a potent stimulus for smooth muscle cell outgrowth from rat aortic explant in vitro **129**, 1

Greenhalgh, R.M., see Powell, J.T. **129**, 41

Guertin, F., see Brunet, S. **129**, 159

Hamilton-Craig, I., see Nestel, P. **129**, 231

Hassan, A., see Neunteufl, T. **129**, 111

Hayashibe, H., K. Asayama, T. Nakane, N. Uchida, Y. Kawada, S. Nakazawa, Increased plasma cholestryler ester transfer activity in obese children **129**, 53

Healy, H., see Westhuyzen, J. **129**, 199

Henderson, B.G., see Wenham, P.R. **129**, 185

Hirano, T., see Yoshino, G. **129**, 33

Holm, G., see Maxwell, S. **129**, 89

Homma, Y., T. Kobayashi, H. Yamaguchi, H. Ozawa, H. Sakane, H. Nakamura, Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebicine (MCI-196) in type II hyperlipoproteinemia **129**, 241

Huber, K., see Kostner, K.M. **129**, 103

Hunt, J.V., see Millican, S.A. **129**, 17

Huppert, F.A., see Galinsky, D. **129**, 177

Igarashi, M., Y. Takeda, S. Mori, K. Takahashi, T. Fuse, M. Yamamura, Y. Saito, Depolymerized holothurian glycosaminoglycan (DHG) prevents neointimal formation in balloon-injured rat carotid artery **129**, 27

Ishikawa, Y., see Shimizu, H. **129**, 193

Janus, E.D., see Tan, K.C.B. **129**, 59

Jessup, W., see Adams, M.R. **129**, 261

Kahri, J., see Tilly-Kiesi, M. **129**, 249

Kato, S., see Miyamoto, T. **129**, 207

Katzenschlager, R., see Neunteufl, T. **129**, 111

Kawada, Y., see Hayashibe, H. **129**, 53

Kazumi, T., see Yoshino, G. **129**, 33

Kennedy, D.G., see Young, P.B. **129**, 67

Kennedy, S., see Young, P.B. **129**, 67

Klaar, U., see Neunteufl, T. **129**, 111

Kobayashi, T., see Homma, Y. **129**, 241

Kohlschütter, A., see Kontush, A. **129**, 119

Kontush, A., A. Reich, K. Baum, T. Spranger, B. Finckh, A. Kohlschütter, U. Beisiegel, Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia **129**, 119

Kostner, K.M., K. Huber, T. Stefanelli, H. Rinner, G. Maurer, Urinary apo(a) discriminates coronary artery disease patients from controls **129**, 103

Labrot, B., see Cremer, P. **129**, 221

Lahdenperä, S., see Tilly-Kiesi, M. **129**, 249

Lam, K.S.L., see Tan, K.C.B. **129**, 59

Lappi, M., see Tilly-Kiesi, M. **129**, 249

Leake, D.S., Does an acidic pH explain why low density lipoprotein is oxidised in atherosclerotic lesions? **129**, 149

Levy, E., see Brunet, S. **129**, 159

Lingenhel, A., see Raal, F.J. **129**, 97

Loughrey, C.M., see McEneny, J. **129**, 215

Luotola, H., see Tilly-Kiesi, M. **129**, 249

Maeda, E., see Yoshino, G. **129**, 33

Makino, I., see Saito, M. **129**, 73

Mak, J.W., see Candlish, J.K. **129**, 49

Mann, H., see Cremer, P. **129**, 221

Maurer, G., see Kostner, K.M. **129**, 103

Maxwell, S., G. Holm, G. Bondjers, O. Wiklund, Comparison of antioxidant activity in lipoprotein fractions from insulin-dependent diabetics and healthy controls **129**, 89

McCredie, R., see Adams, M.R. **129**, 261

McEneny, J., C.M. Loughrey, P.T. McNamee, E.R. Trimble, I.S. Young, Susceptibility of VLDL to oxidation in patients on regular haemodialysis **129**, 215

McNamee, P.T., see McEneny, J. **129**, 215

Meri, S., see Ylitalo, K. **129**, 271

Mero, N., see Eliasson, B. **129**, 79

Millican, S.A., M. Bagga, R. Eddy, M.J. Hutchinson, J.V. Hunt, Effect of glucose-mediated LDL oxidation on the P388D1 macrophage-like cell line **129**, 17

Mitchinson, M.J., see Millican, S.A. **129**, 17

Miyamoto, T., Y. Sasaguri, T. Sasaguri, S. Azakami, H. Yasukawa, S. Kato, N. Arima, K. Sugama, M. Morimatsu, Expression of stem cell factor in human aortic endothelial and smooth muscle cells **129**, 207

Mol, M.J.T.M., Y.B. de Rijke, P.N.M. Demacker, A.F.H. Stalenhoef, Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment **129**, 169

Molloy, A.M., see Young, P.B. **129**, 67

Morimatsu, M., see Miyamoto, T. **129**, 207

Mori, S., see Igarashi, M. **129**, 27

Müller-Berninger, R., see Cremer, P. **129**, 221

Murata, Y., see Yoshino, G. **129**, 33

Nagata, K., see Yoshino, G. **129**, 33

Nagel, D., see Cremer, P. **129**, 221

Nair, C.H., see Shats, E.A. **129**, 9

Nakamura, H., see Homma, Y. **129**, 241

Nakane, T., see Hayashibe, H. **129**, 53

Nakazawa, S., see Hayashibe, H. **129**, 53

Nestel, P., L. Simons, P. Barter, P. Clifton, D. Colquhoun, I. Hamilton-Craig, K. Sikaris, D. Sullivan, A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin **129**, 231

Neunteufl, T., R. Katzenschlager, A. Hassan, U. Klaar, S. Schwarzacher, D. Glogar, P. Bauer, F. Weidinger, Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease **129**, 111

Nuotio, I., see Ylitalo, K. **129**, 271

Ozawa, H., see Homma, Y. **129**, 241

Pagliero, F., see Schreier, L. **129**, 127

Pajukanta, P., see Ylitalo, K. **129**, 271

Paykel, E.S., see Galinsky, D. **129**, 177

Peltonen, L., see Ylitalo, K. **129**, 271

Penney, M.D., see Wenham, P.R. **129**, 185

Pilcher, G., see Raal, F.J. **129**, 97

Porkka, K.V.K., see Ylitalo, K. **129**, 271

Poulter, N.R., see Powell, J.T. **129**, 41

Powell, J.T., R.J. Edwards, P.C. Worrell, P.J. Franks, R.M. Greenhalgh, N.R. Poulter, Risk factors associated with the development of peripheral arterial disease in smokers: a case-control study **129**, 41

Puolakka, J., see Tilly-Kiesi, M. **129**, 249

Pyörälä, T., see Tilly-Kiesi, M. **129**, 249

Raal, F.J., G. Pilcher, D.C. Rubinsztein, A. Lingenhel, G. Utermann, Statin therapy in a kindred with both apolipoprotein B and low density lipoprotein receptor gene defects **129**, 97

Rae, P.W.H., see Wenham, P.R. **129**, 185

Reich, A., see Kontush, A. **129**, 119

Rinner, H., see Kostner, K.M. **129**, 103

Robinson, J., see Adams, M.R. **129**, 261

Rubinsztein, D.C., see Galinsky, D. **129**, 177

Rubinsztein, D.C., see Raal, F.J. **129**, 97

Saha, N., see Candlish, J.K. **129**, 49

Saito, M., M. Eto, I. Makino, Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesterol ester synthesis in human macrophages **129**, 73

Saito, Y., see Igarashi, M. **129**, 27

Sakane, H., see Homma, Y. **129**, 241

Saltissi, D., see Westhuyzen, J. **129**, 199

Sanguinetti, S., see Schreier, L. **129**, 127

Sasaguri, T., see Miyamoto, T. **129**, 207

Sasaguri, Y., see Miyamoto, T. **129**, 207

Schreier, L., F. Pagliero, S. Sanguinetti, R. Wikinski, Influence of the medium on the assessment of LDL resistance to oxidation: lag time in phosphate buffered saline is longer than in sodium chloride solution **129**, 127

Schwarzacher, S., see Neunteufl, T. **129**, 111

Scott, J.M., see Young, P.B. **129**, 67

Seidel, D., see Cremer, P. **129**, 221

Shats, E.A., C.H. Nair, D.P. Dhall, Interaction of endothelial cells and fibroblasts with modified fibrin networks: role in atherosclerosis **129**, 9

Shimizu, H., T. Taniguchi, Y. Ishikawa, M. Yokoyama, Effects of nitric oxide on cholesterol metabolism in macrophages **129**, 193

Shiu, S.W.M., see Tan, K.C.B. **129**, 59

Sikaris, K., see Nestel, P. **129**, 231

Simons, L., see Nestel, P. **129**, 231

Smith, U., see Eliasson, B. **129**, 79

Spranger, T., see Kontush, A. **129**, 119

Stalenhoef, A.F.H., see Mol, M.J.T.M. **129**, 169

Stefenelli, T., see Kostner, K.M. **129**, 103

Sugama, K., see Miyamoto, T. **129**, 207

Sullivan, D., see Adams, M.R. **129**, 261

Sullivan, D., see Nestel, P. **129**, 231

Suurinkeroinen, L., see Ylitalo, K. **129**, 271

Takahashi, K., see Igarashi, M. **129**, 27

Takeda, Y., see Igarashi, M. **129**, 27

Taniguchi, T., see Shimizu, H. **129**, 193

Tan, K.C.B., S.W.M. Shiu, E.D. Janus, K.S.L. Lam, LDL subfractions in acromegaly: relation to growth hormone and insulin-like growth factor-I **129**, 59

Taskinen, M.-R., see Eliasson, B. **129**, 79

Taskinen, M.-R., see Tilly-Kiesi, M. **129**, 249

Taskinen, M.-R., see Ylitalo, K. **129**, 271

Thibault, L., see Brunet, S. **129**, 159

Tilly-Kiesi, M., J. Kahri, T. Pyörälä, J. Puolakka, H. Luotola, M. Lappi, S. Lahdenperä, M.-R. Taskinen, Responses of HDL subclasses, Lp(A-I) and Lp(A-I:A-II) levels and lipolytic enzyme activities to continuous oral estrogen-progestin and transdermal estrogen with cyclic progestin regimens in postmenopausal women **129**, 249

Trimble, E.R., see McEneny, J. **129**, 215

Tysoe, C., see Galinsky, D. **129**, 177

Uchida, N., see Hayashibe, H. **129**, 53

Urayama, T., see Yoshino, G. **129**, 33

Utermann, G., see Raal, F.J. **129**, 97

Vakkilainen, J., see Ylitalo, K. **129**, 271

Viikari, J.S.A., see Ylitalo, K. **129**, 271

Walker, S.W., see Wenham, P.R. **129**, 185

Weidinger, F., see Neunteufl, T. **129**, 111

Weinberg, P.D., see Forster, B.A. **129**, 129

Weir, D.G., see Young, P.B. **129**, 67

Wenham, P.R., B.G. Henderson, M.D. Penney, J.P. Ashby, P.W.H. Rae, S.W. Walker, Familial ligand-defective apolipoprotein B-100: detection, biochemical features and haplotype analysis of the R3531C mutation in the UK **129**, 185

Westhuyzen, J., D. Saltissi, H. Healy, Oxidation of low density lipoprotein in hemodialysis patients: effect of dialysis and comparison with matched controls **129**, 199

Wikinski, R., see Schreier, L. **129**, 127

Wiklund, O., see Maxwell, S. **129**, 89

Worrell, P.C., see Powell, J.T. **129**, 41

Yamaguchi, H., see Homma, Y. **129**, 241

Yamamura, M., see Igarashi, M. **129**, 27

Yasukawa, H., see Miyamoto, T. **129**, 207

Ylitalo, K., K.V.K. Porkka, S. Meri, I. Nuotio, L. Suurinkeroinen, J. Vakkilainen, P. Pajukanta, J.S.A. Viikari, L. Peltonen, C. Ehnholm, M.-R. Taskinen, Serum complement and familial combined hyperlipidemia **129**, 271

Yokoyama, M., see Shimizu, H. **129**, 193

Yoshiko Naka, see Yoshino, G. **129**, 33

Yoshino, G., T. Hirano, E. Maeda, Y. Murata, Yoshiko Naka, K. Nagata, T. Kazumi, T. Urayama, Effect of long-term exogenous hyperinsulinemia and fructose or glucose supplementation on triglyceride turnover in rats **129**, 33

Young, I.S., see McEneny, J. **129**, 215

Young, P.B., S. Kennedy, A.M. Molloy, J.M. Scott, D.G. Weir, D.G. Kennedy, Lipid peroxidation induced in vivo by hyperhomocysteinaemia in pigs **129**, 67

## Subject index

Volume 129 (1997)

ACAT 129, 159  
Acetylated LDL 129, 193  
Acidic pH 129, 149  
Acromegaly 129, 59  
Acylation stimulating protein 129, 271  
Adipsin-acylation stimulating protein 129, 271  
Ageing 129, 177  
Angiotensin converting enzyme 129, 177  
Antioxidants 129, 89, 169  
Apo C-I 129, 177  
Apo E 129, 177  
Apolipoprotein A1 129, 49  
Apolipoprotein B-100 129, 185  
Apolipoprotein B 129, 41, 49  
Apolipoprotein E3/2 129, 73  
Apolipoprotein E 129, 73  
Apolipoproteins 129, 53  
Atherosclerosis 129, 1, 17, 53, 89, 103, 119, 149, 169, 199, 207, 261  
Bile acid sequestrant 129, 241  
Brachial artery 129, 111  
C3a-desArg 129, 271  
Caeruloplasmin 129, 149  
Carotid neointimal thickening 129, 27  
CETP 129, 241  
Child 129, 53  
Cholesterol metabolism 129, 193  
Cholesteryl ester synthesis 129, 73  
Cholesteryl ester transfer protein 129, 53, 59  
Cigarette smoking 129, 79  
c-kit 129, 207  
Combined hyperlipoproteinemia 129, 231  
Complement system 129, 271  
Conjugated diene formation 129, 215  
Copper 129, 127, 149  
Copper-induced lipid peroxidation 129, 215  
Coronary artery disease 129, 111  
Coronary heart disease 129, 119  
Coronary risk factors 129, 221  
Cytokines 129, 169  
Depolymerized holothurian glycosaminoglycan 129, 27  
Diabetes mellitus 129, 169  
Endothelial cells 129, 9, 207  
Endothelium 129, 111  
Endothelium-dependent relaxation 129, 129  
Enhanced chemiluminescence 129, 89  
Evans blue dye 129, 129  
Familial combined hyperlipidemia 129, 271  
Familial defective apo B 100 129, 97  
Familial hypercholesterolemia 129, 97  
Familial ligand-defective apolipoprotein B-100 129, 185  
Fatty acids 129, 199  
Fibrin network structure 129, 9  
Fibroblasts 129, 9  
Flow-mediated vasodilation 129, 111  
Fractional catabolic rate 129, 33  
Fructose 129, 33  
Gemfibrozil 129, 231  
Glucose 129, 17, 33  
Growth hormone 129, 59  
HDL-cholesterol 129, 79  
HDL subclasses 129, 249  
Hemodialysis 129, 199  
Hepatic lipase 129, 59  
Heteroduplex analysis 129, 185  
High-density lipoprotein 129, 89  
Homocysteine 129, 67  
Hypercholesterolemia 129, 185  
Hyperlipidaemia 129, 119  
Hyperlipoproteinemia 129, 241  
Hypertension 129, 119  
Hypertriglyceridemia 129, 73  
In situ hybridization 129, 207  
Insulin-dependent diabetes mellitus 129, 89  
Insulin-like growth factor-I 129, 59  
Insulin resistance syndrome 129, 79  
Iron 129, 149, 159

LCAT **129**, 159, 241  
 LDL **129**, 193  
 LDL cholesterol **129**, 221  
 LDL oxidation **129**, 169  
 LDL-particle size **129**, 79  
 LDL-receptor **129**, 241  
 Leukocytes **129**, 261  
 Lipid hydroperoxides **129**, 215  
 Lipid peroxidation **129**, 67, 119, 199  
 Lipoprotein(a) **129**, 97  
 Lipoprotein(A-I) **129**, 249  
 Lipoprotein A-I **129**, 79  
 Lipoprotein(A-I:A-II) **129**, 249  
 Lipoprotein lipase **129**, 59  
 Lipoproteins **129**, 53, 79, 159, 199  
 Lipoprotein subfraction **129**, 241  
 Liver disease **129**, 119  
 Longevity **129**, 177  
 Long-term hyperinsulinemia **129**, 33  
 Low density lipoprotein **129**, 149, 199  
 Low-density lipoprotein **129**, 89  
 Low density lipoprotein **129**, 17  
 Low density lipoproteins **129**, 1  
 Low tar cigarettes **129**, 41  
 Lysine **129**, 199

Macrophage **129**, 17, 73  
 Macrophages **129**, 193  
 Malondialdehyde **129**, 215  
 Medroxyprogesterone acetate **129**, 249  
 Methylenetetrahydrofolate reductase **129**, 177  
 Myocardial infarction **129**, 221

Nitric oxide **129**, 129, 193, 261  
 Nitrous oxide **129**, 67  
 Norethisterone acetate **129**, 249

Obesity **129**, 53  
 Orang Asli **129**, 49  
 Oxidation **129**, 17  
 Oxidized low density lipoprotein **129**, 127, 149

Percutaneous transluminal coronary angioplasty **129**, 27  
 Peripheral atherosclerosis **129**, 41  
 Peroxidation **129**, 159  
 Phosphate **129**, 127  
 Pigs **129**, 67  
 Plasma lipids **129**, 49  
 Plasma Lp(a) **129**, 103  
 Polymerase chain reaction **129**, 185  
 Postprandial lipemia **129**, 79  
 Predictors of response **129**, 231  
 Prospective cohort study **129**, 221

Rat **129**, 27  
 Risk factor **129**, 103  
 ROC-plot **129**, 103  
 RT-PCR **129**, 207

Salicylate **129**, 159  
 Simvastatin **129**, 231  
 Small dense low density lipoprotein **129**, 59  
 Smoking **129**, 41, 119, 169  
 Smooth muscle cell **129**, 27  
 Smooth muscle cells **129**, 1, 207  
 Statin therapy **129**, 97  
 Stem cell factor **129**, 207  
 Susceptibility to oxidation **129**, 215  
 Systolic hypertension **129**, 41

Transdermal 17 $\beta$ -estrogen **129**, 249  
 Transferrin **129**, 149  
 Triglyceride-rich lipoproteins **129**, 73  
 Triton WR1339 **129**, 33  
 Trypan blue **129**, 129

Ubiquinol-10 **129**, 119  
 Ultrasound **129**, 111

Vitamin B<sub>12</sub> **129**, 67  
 Vitamin E **129**, 89, 169